Wockhardt targets WCK 6777 after Zaynich FDA approval

Why Wockhardt’s antibiotic pipeline is back in focus

Wockhardt has drawn fresh attention after securing US Food and Drug Administration (FDA) approval for its novel injectable antibiotic Zaynich on May 29. The company has positioned Zaynich as a therapy aimed at severe hospital infections caused by resistant Gram-negative pathogens, a segment it places within an antimicrobial resistance (AMR) market estimated at about $1 billion. Days after that approval, chairman Habil Khorakiwala said the company is also betting on another injectable antibiotic candidate, WCK 6777, that could be a similar-scale opportunity.

The comments underline a broader point: Wockhardt is trying to build a portfolio of new-generation antibiotics, rather than relying on a single product. Alongside antibiotics, the company has also referenced a biologics portfolio focused on diabetes therapies such as insulin and GLP-1-based treatments. But the current discussion, both inside and outside the market, is primarily around whether its antibiotic programs can translate scientific progress into commercially meaningful launches.

Zaynich: what the FDA approval changes

Zaynich’s FDA approval is a milestone for Wockhardt as it enters the global market for treatments addressing drug-resistant bacterial infections. The company has said it expects peak sales for Zaynich in the range of $1.5 billion to $1.0 billion annually over the next 4 to 6 years. In its own framing, that expectation is based on the overall AMR market size of about $1 billion and an estimate that a 20% market share could be reasonable.

Wockhardt has also stated it has patent protection for Zaynich until 2038. Separately, it has said it has already secured approval in India and has filed for regulatory approval in Europe, including a reference to filing in Europe in January.

Pricing and rollout plans for Zaynich

Khorakiwala said Zaynich’s full treatment in the US is expected to cost about $10,000 to $12,000 for an 8 to 10 day regimen. That translates to roughly $1,200 to $1,500 per day, based on the same statements. For India, the company has indicated pricing would be about 25% of the US cost.

On the rollout timeline, Wockhardt said the launch process will take about six months, and that it expects to launch in the US by the end of the year, with India potentially earlier. These timelines, if met, would turn the FDA approval into commercial availability in a relatively short window compared with typical global antibiotic launches.

WCK 6777: the next once-a-day injectable bet

Wockhardt’s next big antibiotic focus is WCK 6777, described by the company as a once-a-day injectable antibiotic. Khorakiwala said WCK 6777 has completed Phase I trials in the US. He also suggested it could emerge as an opportunity on a scale similar to Zaynich, while noting uncertainty about how the eventual potential compares.

A key distinction in Wockhardt’s positioning is the care setting. While Zaynich is targeted at severe hospital infections, WCK 6777 is aimed at treatment beyond hospitals through outpatient centres. The company has described WCK 6777 as being developed for multidrug-resistant infections that may continue after a patient is moved out of intensive care or discharged from hospital.

Clinical pathway and the 2030-31 market-entry target

Wockhardt said it plans to begin global clinical trials for WCK 6777, including in India. It expects the product to reach the market around 2030-31. The company has also said it expects to benefit from scientific and regulatory learnings from Zaynich as WCK 6777 advances through clinical development.

Separately, WCK 6777 has received Fast Track designation from the US FDA, with dates referenced in the material as October 2024. The company has described the candidate as relevant for complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).

What else is in Wockhardt’s antibiotic pipeline

Khorakiwala has pointed to other candidates the company is evaluating as potential follow-ons to Zaynich. These include EMROK, described as a drug for Gram-positive infections, and MIQNAF (Nafithromycin), described as being for community-acquired bacterial pneumonia (CABP). The company has also referenced “one more antibiotic” in gram-negative oral, while noting it does not contain zidebactam.

In addition, Wockhardt has mentioned other programs such as WCK 4282 (FOVISCU), which it said completed Phase 2/3 enrollment for cUTI, as well as early-stage candidates including WCK 771 and WCK 2349. It also noted MIQNAF was approved in India in May 2025, with a Phase 3 CABP study published in The Lancet, and that it has been included in 2025 clinical guidelines referenced in the material.

Key facts snapshot

Market impact and investor lens

The FDA approval and the discussion of a second potential blockbuster antibiotic come at a time when Wockhardt has been publicly highlighting the commercial scale it sees for Zaynich. Peak sales guidance of $1.5 billion to $1.0 billion annually over the next 4 to 6 years is material for a company of Wockhardt’s size, and it also anchors how investors may evaluate the rest of the pipeline.

The material also notes that Wockhardt’s stock price has more than doubled over the past year, reflecting improved investor sentiment around its drug discovery program. Even so, the timeline for WCK 6777 is long, with the company itself pointing to 2030-31 as a potential market-entry window.

Analysis: why the outpatient angle matters

Wockhardt is drawing a clear product distinction between Zaynich and WCK 6777 based on where they may be used. Zaynich is framed as a hospital-focused therapy for severe infections, while WCK 6777 is framed as a continuation option when patients move out of intensive care or leave hospital settings. If clinical development supports that positioning, it could expand the addressable treatment setting from inpatient wards to outpatient centres.

The other strategic point is process leverage. Khorakiwala explicitly linked WCK 6777’s development to “scientific and regulatory learnings” from the Zaynich program. In practical terms, that suggests Wockhardt expects prior experience with regulators, trial design, and evidence thresholds in resistant infections to reduce execution risk as it advances a second advanced injectable.

Conclusion

Wockhardt’s FDA approval for Zaynich on May 29 has shifted attention from a single drug milestone to a broader antibiotic platform story. The company is now positioning WCK 6777, a once-a-day injectable aimed at outpatient and post-discharge care, as its next major bet, with global trials planned and a stated market timeline of 2030-31. Near-term, the focus remains on Zaynich’s rollout over the next six months, including the company’s stated plan to launch in the US by the end of the year and potentially earlier in India.